Researchers study prevention of blood clots in cancer patients

October 8, 2008

As more individuals with cancer are being treated as outpatients, the University of Rochester Medical Center is working on an emerging problem: how to prevent the life-threatening blood clots that can accompany some newer cancer drugs.

A team of researchers, awarded $3 million this month by the National Heart, Lung and Blood Institute, is seeking to change the current standard of care by conducting a landmark clinical trial. They will test whether the drug dalteparin, a low-molecule-weight heparin available in a once-daily injection, can prevent pulmonary embolism or other forms of venous thromboembolism (VTE) in patients receiving chemotherapy on an outpatient basis.

The team includes Principal Investigator Charles W. Francis, M.D., professor of Medicine in Hematology/Oncology at the University's James P. Wilmot Cancer Center, and URMC co-investigators Alok A. Khorana, M.D., associate professor of Medicine in Hematology/Oncology, and Mark B. Taubman, M.D., chair of the Department of Medicine and a member of the Aab Cardiovascular Research Institute. Duke University is a research partner as well.

Until recently, physicians had no way to identify which cancer patients might be at higher risk for the clots. But the Rochester group designed a risk model that was published in the journal, Blood. Then, based on input from the Rochester experts, the American Society of Clinical Oncology in 2007 issued its first set of guidelines for clinicians on clot prevention for cancer patients. The next step is to demonstrate that clots can be prevented among those identified as higher risk.

"Venous thromboembolism is one of the leading complications in cancer patients and is the second leading cause of death," Francis said. "We expect that the results of this trial will show the way in preventing these problems and improving care for patients with cancer."

When blood clots develop in the deep veins of the leg or thigh, they can block blood flow and cause pain. In more serious cases, the clot breaks loose and travels to the lungs where it blocks arteries and can be fatal. Being hospitalized or confined to bed rest are risk factors, but clots can also develop in more active people.

Hospitalized patients routinely are given drugs such as dalteparin to prevent or treat the clots as soon as they develop. In the outpatient setting, however, the protocol for cancer treatment does not include using a drug such as Dalteparin for prevention of clots.

"The difficulty for outpatients is that not everyone who has a blood clot is symptomatic," Khorana said. "And in some cases when they do have symptoms of a clot in the lungs, the patient will complain of chest pains, shortness of breath, fatigue or a cough, which can be confused with cancer symptoms."

The Acting United States Attorney General Steven K. Galson, M.D., M.P.H., issued a "call to action" on Sept. 15, 2008, to reduce the number of cases of deep vein thrombosis and pulmonary embolism by urging people to learn more about the condition. The government estimates that up to 600,000 Americans each year suffer from dangerous clots, and that number is expected to rise as the baby-boomer population ages.

Scientists also believe the incidence may be growing with the use of a newer class of cancer therapies called anti-angiogenesis drugs, such as Avastin. Although these newer drugs have less toxicity than chemotherapy, some are associated with higher rates of VTE.

In addition, the properties of some tumors may promote clots. Cancer-associated VTE leads to interruption of therapy, hospitalizations and increased risk of death.

To better understand the biological components of VTE risk in cancers, the Rochester group, led by Taubman, will also study whether elevated levels of tissue factor (TF) in plasma is a predictor of blood clots in cancer patients. Tissue factor is a protein in platelets that plays a vital role in how coagulation occurs and the promotion of blood clots. They will test the TF hypothesis using blood samples and biopsy specimens from patients who enroll in the Dalteparin clinical trial, and from a control group of patients identified as having a low risk of clots.

For years Taubman has been investigating the role of tissue factor in heart disease. But more recently he discovered data that shows certain cancers are also associated with elevated levels of TF, particularly pancreatic cancer. TF levels also tend to be higher in prostate cancer patients who survive for years.

The reasons for increased TF are not completely understood, but scientists do know that as cancer cells grow and die, they dump TF into the bloodstream. Chemotherapy also contributes to more TF entering the bloodstream as the cancer cells die off.

"This grant puts us in the forefront nationally of this growing field of inquiry," Taubman said. "I am confident that we will be the ones to answer the questions about cancer-associated tissue factor and whether anti-coagulant therapy has an effect of the risk of blood clots in cancer patients."

Source: University of Rochester

4.7 /5 (3 votes)  

Rank 4.7 /5 (3 votes)
Relevant PhysicsForums posts

More news stories

Overeating may double risk of memory loss

New research suggests that consuming between 2,100 and 6,000 calories per day may double the risk of memory loss, or mild cognitive impairment (MCI), among people age 70 and older. The study was released today and will be ...

Medicine & Health / Neuroscience

created 1 hour ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Injured boomers beware: Know when to see doctor

(AP) -- It happened to nurse Jane Byron years after an in-line skating fall, business owner Haralee Weintraub while doing "men's" push-ups, and avid cyclist Gene Wilberg while lifting a heavy box.

Medicine & Health / Health

created 6 hours ago | popularity 5 / 5 (1) | comments 0

Starve a virus, feed a cure? Findings show how some cells protect themselves against HIV

A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online ...

Medicine & Health / Research

created 5 hours ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice

Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show t ...

Medicine & Health / Neuroscience

created Feb 09, 2012 | popularity 4.9 / 5 (58) | comments 15 | with audio podcast

Green tea found to reduce disability in the elderly

(Medical Xpress) -- A lot of research has been done over the past several years looking into the health benefits of green tea. As a result, scientists have found that regular consumption of the beverage leads ...

Medicine & Health / Health

created Feb 07, 2012 | popularity 4.4 / 5 (15) | comments 10 | with audio podcast report


Google might launch Drive for cloud storage soon

(PhysOrg.com) -- Google's next big move, according to the Wall Street Journal, is a cloud storage service called Drive. Hardly first to the plate, Google is simply catching up to introducing its cloud reposi ...

Scientists discover molecular secrets of 2,000-year-old Chinese herbal remedy

For roughly two thousand years, Chinese herbalists have treated Malaria using a root extract, commonly known as Chang Shan, from a type of hydrangea that grows in Tibet and Nepal. More recent studies suggest that halofuginone, ...

New method to examine batteries -- MRI from the inside

There is an ever-increasing need for advanced batteries for portable electronics, such as phones, cameras, and music players, but also to power electric vehicles and to facilitate the distribution and storage of energy derived ...

Lab study raises questions over nano-particle impact

Tests involving chickens have raised questions about the impact on health from engineered nano-particles, the ultra-fine grains commonly used in drugs and processed foods, scientists said on Sunday.

A mitosis mystery solved: How chromosomes align perfectly in a dividing cell

Although the process of mitotic cell division has been studied intensely for more than 50 years, Whitehead Institute researchers have only now solved the mystery of how cells correctly align their chromosomes during symmetric ...

Researchers find extensive RNA editing in human transcriptome

In a new study published online in Nature Biotechnology, researchers from BGI, the world's largest genomics organization, reported the evidence of extensive RNA editing in a human cell line by analysis of RNA-seq data, demons ...